SYRS Stock Overview · Revenue is forecast to grow % per year · Highly volatile share price over the past 3 months · Has less than 1 year of cash runway. Get the latest Syros Pharmaceuticals Inc (SYRS) real-time quote, historical performance, charts, and other financial information to help you make more. Syros Pharmaceuticals (NASDAQ:SYRS) Stock Quotes, Forecast and News Summary ; Close, - ; Volume / Avg. K / K ; Day Range, $ - $ ; 52 Wk Range. Discover real-time Syros Pharmaceuticals, Inc. Common Stock (SYRS) stock prices, quotes, historical data, news, and Insights for informed trading and. Here's Why Syros Pharmaceuticals Is Collapsing Today The company announced the pricing of a stock offering. Despite the dilution, it's a well-timed move by.
One share of SYRS stock can currently be purchased for approximately $ Is Syros Pharmaceuticals, Inc. listed on the NASDAQ or NYSE? Syros Pharmaceuticals Inc Registered ShsStock, SYRS ; Balance Sheet in Mio. USD · Total liabilities, ; Key Data in USD · Sales per share, Syros Pharmaceuticals Inc SYRS:NASDAQ · Open · Day High · Day Low · Prev Close · 52 Week High · 52 Week High Date01/02/24 · 52 Week Low Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Get Free Report) saw unusually large options trading on Tuesday. Stock traders bought 5, put options on the. Syros Pharmaceuticals stock is down on Tuesday as SYRS investors react to the company discontinuing enrollment for a clinical trial. Today's Biggest Pre-Market. View live Syros Pharmaceuticals, Inc. chart to track its stock's price action. Find market predictions, SYRS financials and market news. Latest SYRS News · Stocks. Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination · Stocks. Syros Pharmaceuticals (SYRS) Loses % in 4 Weeks, Here's. Get Syros Pharmaceuticals Inc (profhimservice52.ru) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments. Below are the latest news stories about SYROS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SYRS as an investment opportunity. View Syros Pharmaceuticals, Inc. SYRS stock quote prices, financial information, real-time forecasts, and company news from CNN. Complete Syros Pharmaceuticals Inc. stock information by Barron's. View real-time SYRS stock price and news, along with industry-best analysis.
SYRS vs Biotech Stocks ; $M · %, x, x ; $M · +%, x, x. Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why. Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene. SYRS Syros Pharmaceuticals Inc. 2, $ $ (%). Today. Watchers, 2, Wk Low, $ Wk High, $ Market Cap, $M. View Syros Pharmaceuticals (SYRS) stock price, news, historical charts, analyst ratings, financial information and quotes on Moomoo. Syros reports first quarter financial results and provides a corporate update. May 7, Syros to participate in upcoming investor conferences. Syros Pharmaceuticals Inc Stock Price (SYRS) Syros Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SYRS. The. SYRS | Complete Syros Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Syros Pharmaceuticals Stock Smart Score ; Analyst Consensus. Strong Buy. Average Price Target: $ (% Upside) ; Blogger Sentiment. Bullish. SYRS. View the latest Syros Pharmaceuticals Inc. (SYRS) stock price, news, historical charts, analyst ratings and financial information from WSJ.
News. $ %. Previous Close Open 52 Week Low 52 Week EPS PRIOR. EPS. Rev guidance. $10,,, SYRS Stock. In the current month, SYRS has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SYRS average Analyst price target in the past 3 months is $ Syros Pharmaceuticals (SYRS) · After Hours PM ET 08/23/ $ %. Previous Close · $ · ; % · Volume: , · Volume % Chg: 49%. Latest SYRS News From Around the Web · Syros Announces Pricing of $ million Underwritten Offering of Common Stock and Pre-Funded Warrants · individual. HC Wainwright & Co. analyst Andrew Fein reiterates Syros Pharmaceuticals (NASDAQ:SYRS) with a Buy and maintains $15 price target. BenzingaMay 15 ET.
3 Chase Credit Cards | A Complete Guide To The Futures Markets